Tyme Technologies, Inc.

NasdaqCM:TYME Voorraadrapport

Marktkapitalisatie: US$53.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Tyme Technologies Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Richie Cunningham

Algemeen directeur

US$1.3m

Totale compensatie

Percentage CEO-salaris41.97%
Dienstverband CEO1.8yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn2.7yrs
Gemiddelde ambtstermijn bestuur6.1yrs

Recente managementupdates

Recent updates

Seeking Alpha • Sep 15

Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger

Shareholders of Syros Pharmaceuticals (NASDAQ:SYRS) and Tyme Technologies (NASDAQ:TYME) on Thursday voted in favor of the merger between the two biotech companies. SYRS and TYME stock gained more than 20% each in aftermarket trading - SYRS +22% and TYME +24%. Both SYRS and TYME held special stockholder meetings to vote on the merger, the companies said in a statement. SYRS shareholders also voted in favor of the company's concurrent private investment in public equity (PIPE) financing. The closing of the merger and the PIPE financing are anticipated to take place on or around Sept. 16. Post the closing of the merger, the combined company will trade on the Nasdaq under the ticker symbol "SYRS". SYRS also announced a 1-for-10 reverse stock split, with the stock to begin trading on a split-adjusted basis on the Nasdaq on Sept. 19.
Analyseartikel • Aug 05

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 05

TYME stock surges on merger agreement and Syros Pharmaceuticals

Development stage biotech firms Syros Pharmaceuticals (SYRS) and Tyme Technologies (NASDAQ:TYME) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros (SYRS) will acquire Tyme (TYME). Tyme (TYME) has added ~23% in the pre-market so far while Syros (SYRS) is trading ~6% higher. Per the terms, Syros (SYRS) will issue ~74.3M shares of its common stock to TYME investors and TYME stockholders are entitled to nearly 0.4312 shares of Syros (SYRS) common stock for each TYME stock they hold. The deal is worth about $60M net of wind-down and transaction expenses. Following the merger, the combined entity will be led by Syros’ existing management team and trade on Nasdaq under the ticker symbol “SYRS.” Separately, Syros (SYRS) disclosed an oversubscribed $130M financing of private investment in public equity (PIPE) to purchase a total of up to 138.1M additional shares of common stock at $0.94 apiece. In addition, Syros (SYRS) also announced an amendment to its senior secured loan facility with Oxford Finance LLC. The terms include one year extension to the interest-only payment period and maturity dates subject to conditions revising them to March 1, 2024, and February 1, 2026, respectively. The transactions are expected to close in H2 2022.
Seeking Alpha • May 26

Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives

Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives. Board seems to be leaning towards a sale of the company.
Analyseartikel • Mar 19

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 07

Tyme Technologies Offers Incredible Risk-Reward

Tyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices. I review some of the company’s updates and point out a few bullish highlights for investors. In addition, I discuss some of my lingering downside risks for TYME. I update investors on my strategy for managing my TYME position and how I intend to take advantage of the sell-off.
Analyseartikel • Nov 19

Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 27

Tyme Technologies: The Market Missed The Bullish Memo

Tyme Technologies recently made some big moves following a strategic review. I believe the market has missed the bullish memo about these changes. I review some of these significant changes and provide a bullish memo for investors. In addition, I discuss how these changes have addressed my downside concerns. The recent sell-off provided me with an opportunity to load up near the 52-week lows. I update investors on my strategy for managing my TYME position.
Analyseartikel • Jul 19

We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Mar 26

Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analyseartikel • Feb 19

Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?

Investors may wish to note that an insider of Tyme Technologies, Inc. , Michael Demurjian, recently netted US$55k from...
Analyseartikel • Feb 02

Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?

A look at the shareholders of Tyme Technologies, Inc. ( NASDAQ:TYME ) can tell us which group is most powerful...
Analyseartikel • Dec 16

Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?

We wouldn't blame Tyme Technologies, Inc. ( NASDAQ:TYME ) shareholders if they were a little worried about the fact...
Analyseartikel • Dec 09

Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analyse CEO-vergoeding

Hoe is Richie Cunningham's beloning veranderd ten opzichte van Tyme Technologies's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2022n/an/a

-US$24m

Mar 31 2022US$1mUS$564k

-US$24m

Dec 31 2021n/an/a

-US$24m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021US$2mUS$194k

-US$29m

Compensatie versus markt: De totale vergoeding ($USD 1.34M ) Richie } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.34K ).

Compensatie versus inkomsten: De vergoeding van Richie is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Richie Cunningham (51 yo)

1.8yrs
Tenure
US$1,344,080
Compensatie

Mr. Richard Cunningham, also known as Richie, serves as Chief Executive Officer and Director at Tyme Technologies, Inc. since November 23, 2020. Mr. Cunningham had been the Chief Executive Officer and Pres...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Richard Cunningham
CEO & Director1.8yrsUS$1.34mgeen gegevens
Steven Hoffman
Co-Founder & Director9.2yrsUS$2.60m11.63%
$ 6.2m
Frank Porfido
Chief Financial Officer1.3yrsUS$1.29m0.0058%
$ 3.1k
James Biehl
Chief Legal Officer & Secretary4yrsUS$1.19m0.061%
$ 32.7k
Jonathan Eckard
Chief Business Officer3.5yrsUS$858.79kgeen gegevens
Jan Van Tornout
Acting Chief Medical Officer1.4yrsgeen gegevens0.0057%
$ 3.1k
2.7yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van TYME wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Richard Cunningham
CEO & Director1.8yrsUS$1.34mgeen gegevens
Steven Hoffman
Co-Founder & Director7.5yrsUS$2.60m11.63%
$ 6.2m
Timothy Tyson
Independent Director7.5yrsUS$138.73k0.0034%
$ 1.8k
Donald DeGolyer
Independent Director4.3yrsUS$146.99kgeen gegevens
Douglas Michels
Independent Chairman3.9yrsUS$166.34k0.064%
$ 34.2k
David Carberry
Independent Director5.5yrsUS$148.24k0.058%
$ 31.1k
Gerald Sokol
Independent Director & Member of Medical Advisory Board7.5yrsUS$122.87k0.0034%
$ 1.8k
Suresh Chari
Member of Medical Advisory Board6.7yrsgeen gegevensgeen gegevens
Paul Oberstein
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Marcus Noel
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Allyson Ocean
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Vincent Picozzi
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
6.1yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TYME wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2022/09/16 03:23
Aandelenkoers aan het einde van de dag2022/09/16 00:00
Inkomsten2022/06/30
Jaarlijkse inkomsten2022/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Tyme Technologies, Inc. wordt gevolgd door 3 analisten. van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Arlinda LeeCanaccord Genuity
Joshua SchimmerEvercore ISI
Swayampakula RamakanthH.C. Wainwright & Co.